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AbstrAct
About 1.4 British million people are at risk of strokes 
due to non-valvular atrial fibrillation (AF) necessitating 
long-term anticoagulation. The vitamin K antagonist, 
warfarin, has a long half-life and narrow therapeutic 
range necessitating regular monitoring and is a common 
cause of iatrogenic hospital admission. Direct-acting oral 
anticoagulants (DOACs), dabigatran, rivaroxaban, apixaban 
and edoxaban are not required to have monitoring but are 
sensitive to changes in renal function and are associated 
with poorer adherence. There are good grounds to believe 
that DOACs are not always superior to warfarin in routine 
practice particularly with an older population. Much higher 
levels of therapeutic effectiveness can be achieved using a 
simple genotype guidance to identify those who are highly 
sensitive and by adoption of home monitoring. These 
adjustments could make warfarin the preferred drug for 
most people and would reduce the dramatic rise in health 
service expenditure.
 
It is estimated that 1.4 British million people 
are at risk of strokes due to non-valvular 
atrial fibrillation (AF) including about 4% 
of the over 80s.1 Antiplatelet agents are inef-
fective necessitating long-term anticoagula-
tion.2 3 The S-isoform of the current standard, 
warfarin, works by interfering with vitamin K 
activation of clotting factors II, VII, IX and 
X.4 Its long half-life and narrow therapeutic 
range necessitate regular monitoring using 
the international normalised ratio (INR) 
which needs to be held in a range of 2–3 
to minimise clot formation or the converse, 
uncontrolled bleeding.5–7 The latter is one 
of the most common causes of iatrogenic 
hospital admission.8
Two strategies have emerged to improve the 
clinical utility of preventive anticoagulation: 
(a) the development of a new class of anti-
coagulants, known as the direct-acting oral 
anticoagulants (DOACs), including dabiga-
tran, rivaroxaban, apixaban and edoxaban; 
and (b) better optimisation of warfarin use by 
understanding the common genetic variation 
in drug response and by making INR testing 
and dose adjustment more convenient with 
self-testing devices.
A series of large-scale randomised 
controlled trials (RCTs) published over the 
last five years have demonstrated apparent 
superiority of DOACs over warfarin for key 
indicators coupled with the advantage of 
a wider therapeutic range and a lack of a 
need for regular monitoring of the degree 
of anticoagulation.9–11 This resulted in the 
UK National Institute for Health and Care 
Excellence (NICE) guidance in 2014 that the 
approaches should be given equal weight at 
patient initiation consultations (http:// nice. 
org. uk/ guidance/ cg180) and subsequently a 
more direct endorsement of DOACs by the 
European Society of Cardiology.12 As a result, 
there is a major shift towards DOACs in clin-
ical practice which is placing a significant 
burden on health budgets. In the National 
Health Service (NHS) in England, expendi-
ture on anticoagulants rose by >£100 million 
in 2015/2016 and by around £400 million in 
the last financial yeari. On present trends, the 
cost will rise to £1 billion per year by 2020, 
representing 5% of the total drug budget. 
While the price will begin to fall in 2022 as 
patents expire, these costs justify a critical 
examination of the available evidence.
The first DOAC to be licensed, dabiga-
tran, is a thrombin inhibitor. Some degree 
of interpersonal variation in response was 
not made clear in initial submissions leading 
to a prolonged legal challenge.13 A reversal 
agent, idarucizumab, is now licensed in the 
UK but is very expensive, costing >£2500 per 
use as opposed to parenteral vitamin K as a 
reversal agent for warfarin.14 The other three 
licensed agents—rivaroxaban, apixaban and 
edoxaban—are direct inhibitors of activated 
factor X. Andexanet alfa, a reversal agent of 
i Primary care data are from the Business Services 
Authority. Secondary care data are derived from 
the NICE ‘Novel Oral Anticoagulant’ Technology 
Assessment.
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factor Xa inhibitor activity, is under consideration to be 
licensed in the UK though its short half-life and high cost 
of >£1500 is an issue.15 The most frequently prescribed 
anti-Xa inhibitor, rivaroxaban, was shown to be non-infe-
rior to warfarin in a large-scale trial which used a device 
for INR monitoring in the warfarin arm which was subse-
quently withdrawn on the US Food and Drug Administra-
tion instruction as it was unreliable.16 The original study 
authors concluded this had not compromised the final 
conclusions.
A meta-analysis of the four RCTs comparing efficacy of 
DOACs versus warfarin found the DOACs to be superior 
to warfarin in terms of embolic and haemorrhagic stroke 
but to be inferior in terms of gastrointestinal bleeding 
events.17 An important qualification was that superiority 
was dependent on the proportion of warfarin patients 
in the therapeutic window. If the average time in the 
therapeutic range (TTR) was <66%, the new drugs were 
superior but they were not superior if average TTR of 
patients on warfarin was >66% (Relative Risk =0.69, 95% 
CI 0.59 to 0.81 vs Relative Risk=0.93, 95% CI 0.76 to 1.13, 
Pinteraction=0.022).
Three other subsequent observations raise major 
concerns. RCTs tend to focus on younger people with 
fewer comorbidities. Abrahams et al18 reported in 2015 
that adverse events were more common in the older 
population. This has a plausible biological basis since 
excretion rates are pivotal to maintaining correct ther-
apeutic levels. DOACs are more dangerous in people 
with impaired renal function. In the frail elderly popu-
lation, intercurrent illness can lead to acute decline in 
renal function leading to excessive anticoagulation and 
sometimes life-threatening bleeding. Guidance suggests 
that renal function should be regularly checked but 
compliance with this guidance is thought to be poor 
in practice. The importance of drug–drug interactions 
with DOACs is underappreciated and can occur with 
drugs used intermittently, for example, antibiotics such 
as clarithromycin. The lack of validated laboratory tests 
to monitor the degree of anticoagulation with DOACs 
means that any dose reduction in patients with impaired 
renal function or on interacting drugs is empirical.
The second major concern is adherence. A recent anal-
ysis (figure 1) has revealed much poorer adherence for 
the DOACs probably due to the lack of routine moni-
toring and in the case of dabigatran and apixaban, the 
need for twice-daily use. This analysis of adherence in 
England is based on a representative review of repeat 
prescription issuance and reveals a worrying decline in 
correct use over the first 12 months to just over half for 
rivaroxaban and apixaban and to 34% for dabigatran. 
These levels compare unfavourably with the 74% adher-
ence for warfarin. Similar results have been reported in 
Canada.19 When the different age profile of patients in 
clinical practice and these new data on adherence are 
factored in, it becomes less likely that the DOACs will 
be superior to warfarin and are likely to be inferior. In 
those centres where TTR is >70%, these drugs are almost 
certainly inferior in routine practice. It is noteworthy that 
there is currently no systematic assessment of warfarin 
monitoring services. This would allow commissioners to 
make a more objective assessment of the current trend 
towards DOACs as treatment of first choice.
The third area of concern is the association between 
the use of DOACs and myocardial infarction. This 
was initially identified with dabigatran and has been 
confirmed by meta-analysis.20 Although initially dismissed 
as due to a protective effect of warfarin, rather than an 
Figure 1 Adherence data for oral anticoagulants in 380 nationally distributed general practices (2143 general practitioners) in 
September 2016 using selected InPS Vision clinical systems. AF, atrial fibrillation.
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adverse effect of dabigatran, a recent mechanistic study 
has shown that dabigatran increases platelet adhesion 
and aggregation.21 Worryingly, more recently, it has been 
suggested in an observational study,22 and in a meta-anal-
ysis of randomised trials, that the anti-Xa DOACs may 
also increase the risk of myocardial infarction.23 Further 
studies are needed in this area to reduce any confounders 
and should include a mechanistic evaluation.
A possible tipping point in the debate has emerged 
recently; a systematic review of warfarin use and cancer 
rates using comprehensive Norwegian population-based 
ascertainment involving >1.2 million people has revealed 
a significant reduction in common cancers among 
warfarin users (Incident Rate Ratio 0.84, CI 0.82 to 
0.86).24 Secondary analysis focused on those with AF 
revealed an incidence rate ratio of 0.62 (CI 0.59 to 0.65) 
with a relative risk of only 0.39 for lung cancer. In vitro 
studies support an anticancer effect, possibly mediated 
via the vitamin K-dependent product of the gene Gas6, 
the ligand for Axl receptor tyrosine kinase. If this obser-
vation is confirmed, the case for preferring warfarin, 
especially in the older population, becomes convincing.
There have been two major developments which make 
it possible to further improve the clinical outcomes 
in patients on warfarin. It has been recognised for 20 
years that approximately 34% of the population carry 
one of two variants, known as *2 (rs1799853) and *3 
(rs1057910), in the CYP2C9 gene which is responsible 
for breakdown of the more active S-form of warfarin.25 
People who are homozygous for either or doubly hetero-
zygous have a much slower decline in warfarin levels 
and require much lower maintenance doses. Stability is 
harder to achieve and TTR is reduced. A second gene, 
VKORC1, codes for the enzyme targeted by warfarin. A 
common variant c.1639 G >A(rs9923231), present in 58% 
of the population, reduces the expression of this gene 
and hence reduced levels of the enzyme, making the 
coagulation system more sensitive to the inhibitory effects 
of warfarin.26 When the declining metabolic capacity with 
age and the increased drug needs of the overweight are 
factored in, there is a 40-fold variation in weekly warfarin 
needs. The EU-PACT trial demonstrated that genotyping 
at induction allowed rapid adoption of the correct dose 
with a more rapid achievement of a therapeutic level and 
greater time in range.27 The device used in the EU-PACT 
trial allowed genotyping to be done in under 2 hours 
without significant technical expertise and is now being 
evaluated in a variety of near patient settings. Other 
devices are under development which promise even 
faster and easier genotyping and dose calculation. Mega 
et al28 demonstrated the impact of genotyping for CYP2C9 
and VKORC1 in a trial of edoxaban versus warfarin; in 
those at genotypic low risk, there was no difference in 
bleeding risk compared with the DOAC.
A second technical innovation has been the develop-
ment of a hand-held INR testing device, the COAGu-
CHEK that is sufficiently simple to operate that people 
are able to test their INR at home and call in the result, 
eventually graduating in some cases to self-manage-
ment of warfarin dose. A pilot study in the northeast 
of England has shown considerable enthusiasm among 
warfarin users, even those of advanced years; TTR levels 
of ≥80% have been recorded. In the NHS in England, the 
combined cost of warfarin prescription and annual INR 
monitoring, whether centrally organised and delivered 
or employing self-testing, is around £200 per annum. The 
annual prescription cost of the DOACs is in the range 
£600–800 to which should be added the cost of biannual 
renal function checks.
Although we have focused on anticoagulation in AF, 
similar considerations apply to venous thromboembo-
lism. Projects are under way in the UK Academic Health 
Science Networks to deploy the combination of routine 
genotyping and self-testing to confirm the efficacy of 
more effective targeting of warfarin. Meanwhile, the 
NHS expenditure on anticoagulation is climbing steeply. 
DOACs account for 31% of treated patients but around 
93% of expenditure on anticoagulants. Uptake of the new 
drugs varies widely, ranging from 8% to >60% in different 
Clinical Commissioning Groups across Englandi. As 
new warfarin patients decline and DOAC share of the 
market increases, expenditure will rise steeply despite 
the lack of evidence of efficacy in routine practice. Even 
allowing for the initial cost of genotyping of around £50, 
routine monitoring, typically £150 per annum which can 
include the depreciated £300 cost for self-testing devices 
on a lease arrangement, warfarin offers major savings. 
Warfarin costs an average of £0.83 per month, whereas 
the average monthly cost of DOACs is listed at just >£50. 
Thus, overall NHS annual expenditure could be reduced 
by >£0.5B per annum in the near future without impair-
ment of the nation’s health if DOACs are restricted to 
those of working age and/or are shown to be sensitive to 
warfarin.
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